Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy
Cancers · 25.06.2026 · 18 (13) · 2069
DOI: 10.3390/cancers18132069 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.06.2026. Verfasst von Flavio Donnini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) remains the most lethal primary brain tumor in adults, with a median overall survival of approximately 15–20 months despite multimodal treatment including surgery, chemoradiation, and Tumor Treating Fields (TTFields). While the survival benefit of TTFields was established by the EF-14 phase III trial, their biological effects extend well beyond the canonical anti-mitotic mechanism and encompass extensive interactions with the GBM tumor microenvironment (TME). This review provides an integrated mechanistic analysis of TTFields–TME interactions in GBM, with a distinctive focus on their convergence with radiotherapy. We examine how TTFields activate innate immune sensing through cGAS/STING and AIM2 inflammasome pathways, drive immunogenic cell death, reprogram tumor-associated macrophages, and prime adaptive T cell responses. We further address TTFields effects on glioma stem cells, blood–brain barrier permeability, and intracellular signaling governing invasion, angiogenesis, and autophagy. Critically, we develop the mechanistic and clinical case for TTFields-radiotherapy combinations, highlighting convergent mechanisms of DNA repair impairment, mitotic catastrophe, and innate immune activation. Practical considerations for concurrent clinical implementation are discussed alongside a research agenda centered on optimal timing, hypofractionation, and predictive biomarkers. Available evidence—largely preclinical—suggests that TTFields may act as a TME-remodeling platform whose potential is most likely to be realized through mechanistically informed combinations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
- Unit of Neurosurgery, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
- Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, 00185 Rome, Italy.
- IRCCS Neuromed, 86077 Pozzilli, Italy.
ORCID-Profile: Flavio Donnini, Paolo Tini
Zitieren
APA
Donnini, F., Battaglia, G., Chibbaro, S., Marampon, F., Minniti, G., & Tini, P. (2026). Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy. Cancers, 18(13), 2069. https://doi.org/10.3390/cancers18132069
Vancouver
Donnini F, Battaglia G, Chibbaro S, Marampon F, Minniti G, Tini P. Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy. Cancers. 2026;18(13):2069. doi:10.3390/cancers18132069
BibTeX
@article{Donnini2026,
author = {Donnini, Flavio and Battaglia, Giuseppe and Chibbaro, Salvatore and Marampon, Francesco and Minniti, Giuseppe and Tini, Paolo},
title = {Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2069},
doi = {10.3390/cancers18132069}
}
EUVIMED